Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Osamu Yasumuro

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Pharmaceutical Health Care and Sciences|July 10, 2026
Syndrome of inappropriate antidiuretic hormone secretion following immune effector cell-associated neurotoxicity syndrome during blinatumomab therapy: a case reportMisato Yoshihara, Satoshi Yuyama, Osamu Yasumuro, et al.
Journal of Pharmaceutical Health Care and Sciences|August 19, 2025
Impact of concomitant use of pazopanib and gastric acid suppressants on progression-free survival and safety in patients with sarcoma: a retrospective studyTatsuya Isezaki, Hitomi Yuyama, Osamu Yasumuro, et al.
Journal of Clinical Pharmacology|April 6, 2022
Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D<sub>3</sub> )/Calcium SupplementKeisuke Ikegami, Masayuki Hashiguchi, Hayato Kizaki, et al.
Biological & Pharmaceutical Bulletin|January 3, 2023
Investigation of Prescription Status and Exploration of Risk Factors Related to Denosumab-Induced Hypocalcemia in Combination Therapy with 1α,25-Dihydroxy-vitamin D<sub>3</sub>Keisuke Ikegami, Megumi Saito, Shungo Imai, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 24, 2017
Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in ratsOsamu Yasumuro, Shinya Uchida, Yasuharu Kashiwagura, et al.
Journal of Pharmaceutical Health Care and Sciences|October 28, 2025
Assessing the utility and challenges for implementation of a risk prediction system: a usability study with hospital pharmacistsKeisuke Ikegami, Masami Tsuchiya, Hayato Kizaki, et al.
Biological & Pharmaceutical Bulletin|June 18, 2025
Validation of Risk Prediction System for Denosumab-Induced Hypocalcemia with an External Clinical DatasetKeisuke Ikegami, Masami Tsuchiya, Shungo Imai, et al.
Studies in Health Technology and Informatics|August 8, 2025
Development of an Automated Classification System for Medication-Related Incident Factors: A Practical Approach to Enhancing Patient Safety ManagementYuri Takamatsu, Sayaka Ebara, Hayato Kizaki, et al.
JCO Clinical Cancer Informatics|July 15, 2024
External Validation and Update of the Risk Prediction Model for Denosumab-Induced Hypocalcemia Developed From a Hospital-Based Administrative DatabaseKeisuke Ikegami, Shungo Imai, Osamu Yasumuro, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Pharmaceutical Health Care and Sciences|July 10, 2026
Syndrome of inappropriate antidiuretic hormone secretion following immune effector cell-associated neurotoxicity syndrome during blinatumomab therapy: a case reportMisato Yoshihara, Satoshi Yuyama, Osamu Yasumuro, et al.
Journal of Pharmaceutical Health Care and Sciences|August 19, 2025
Impact of concomitant use of pazopanib and gastric acid suppressants on progression-free survival and safety in patients with sarcoma: a retrospective studyTatsuya Isezaki, Hitomi Yuyama, Osamu Yasumuro, et al.
Journal of Clinical Pharmacology|April 6, 2022
Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D<sub>3</sub> )/Calcium SupplementKeisuke Ikegami, Masayuki Hashiguchi, Hayato Kizaki, et al.
Biological & Pharmaceutical Bulletin|January 3, 2023
Investigation of Prescription Status and Exploration of Risk Factors Related to Denosumab-Induced Hypocalcemia in Combination Therapy with 1α,25-Dihydroxy-vitamin D<sub>3</sub>Keisuke Ikegami, Megumi Saito, Shungo Imai, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 24, 2017
Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in ratsOsamu Yasumuro, Shinya Uchida, Yasuharu Kashiwagura, et al.
Journal of Pharmaceutical Health Care and Sciences|October 28, 2025
Assessing the utility and challenges for implementation of a risk prediction system: a usability study with hospital pharmacistsKeisuke Ikegami, Masami Tsuchiya, Hayato Kizaki, et al.
Biological & Pharmaceutical Bulletin|June 18, 2025
Validation of Risk Prediction System for Denosumab-Induced Hypocalcemia with an External Clinical DatasetKeisuke Ikegami, Masami Tsuchiya, Shungo Imai, et al.
Studies in Health Technology and Informatics|August 8, 2025
Development of an Automated Classification System for Medication-Related Incident Factors: A Practical Approach to Enhancing Patient Safety ManagementYuri Takamatsu, Sayaka Ebara, Hayato Kizaki, et al.
JCO Clinical Cancer Informatics|July 15, 2024
External Validation and Update of the Risk Prediction Model for Denosumab-Induced Hypocalcemia Developed From a Hospital-Based Administrative DatabaseKeisuke Ikegami, Shungo Imai, Osamu Yasumuro, et al.
Pageof 1